Results 141 to 150 of about 4,759 (180)
Some of the next articles are maybe not open access.
PHARMACEUTICAL CARE: SIBO IN THE COMMUNITY PHARMACY.
Revista sanitaria de investigación, 2023SIBO son las siglas como se conoce al Sobre-Crecimiento Bacteriano del Intestino Delgado, como su nombre indica se caracteriza por aumento excesivo de las bacterias intestinales que conlleva un conjunto de síntomas, como son hinchazón, diarrea y/o estreñimiento, además de dolor abdominal.
openaire +1 more source
The Spectrum of Small Intestinal Bacterial Overgrowth (SIBO)
Current Gastroenterology Reports, 2019To critically review recent (past 3 years) literature on the definition, diagnosis, and management of small intestinal bacterial overgrowth (SIBO).While various series continue to illustrate the occurrence of SIBO in disease states where well-known risk factors for its occurrence are present (hypochlorhydria, disorders of intestinal structure or motor ...
openaire +2 more sources
Alternative therapies in health and medicine, 2019
Small intestinal bacterial overgrowth (SIBO) has gained popularity on the internet in addition to certain clinical and research circles. This interest has expanded awareness of important new dietary, nutraceutical, and pharmaceutical treatments in addition to laboratory evaluation assessment options.
openaire +1 more source
Small intestinal bacterial overgrowth (SIBO) has gained popularity on the internet in addition to certain clinical and research circles. This interest has expanded awareness of important new dietary, nutraceutical, and pharmaceutical treatments in addition to laboratory evaluation assessment options.
openaire +1 more source
The analysis of protein consumption patterns in patients with SIBO
The FASEB Journal, 2017Small intestinal bacterial overgrowth (SIBO) is common in patients with gastrointestinal diseases. SIBO symptoms are improved with antimicrobial treatment, but recurrence rate is high (approximately 40%). Dietary modification is essential for prevention of recurrence of SIBO however there are no detailed studies of nutrition in SIBO patients.
Vasily Isakov +2 more
openaire +1 more source
The IBS and SIBO dilemma: Here we go again
Digestive and Liver DiseaseNA
Marasco, Giovanni +2 more
openaire +4 more sources
La Revue de medecine interne
Digestive functional disorders are among the most frequent reasons for medical consultation and a significant source of medical wandering. Therapeutic management of these patients is difficult, particularly due to the absence of specific treatment linked to an incomplete understanding of the pathophysiological mechanisms.
Thomas, Escoda +3 more
openaire +1 more source
Digestive functional disorders are among the most frequent reasons for medical consultation and a significant source of medical wandering. Therapeutic management of these patients is difficult, particularly due to the absence of specific treatment linked to an incomplete understanding of the pathophysiological mechanisms.
Thomas, Escoda +3 more
openaire +1 more source
SIBO: diagnòstics, tractaments i enfocaments actuals
TECA: Tecnologia i Ciència dels AlimentsEl sobrecreixement bacterià de l’intestí prim (SIBO, de l’anglès small intestinal bacterial overgrowth) és una alteració de la microbiota intestinal caracteritzada per una proliferació excessiva i/o anòmala de bacteris o arqueus en aquest segment intestinal, amb implicacions clíniques rellevants.
Rubio-Pérez, Irene +2 more
openaire +1 more source
393 Optimising Post-Surgical Assessment for SIBO
British Journal of SurgeryAbstract Introduction The postsurgical screening for small intestinal bacterial overgrowth (SIBO) based on hydrogen breath test (BT) can be equivocal which may require optimising. Method BTs were performed using 20g ...
Ismail Miah +3 more
openaire +1 more source
SIBO – pharmacotherapy, supportive therapies, and the impact of comorbidities
The article presents current therapeutic strategies used in the treatment of small intestinal bacterial overgrowth (SIBO) and discusses the role of comorbidities affecting treatment efficacy and the risk of SIBO recurrence. Standard SIBO therapy involves the use of rifaximin and, in cases of methane-producing SIBO (IMO), metronidazole and neomycin ...Świder, Marta, Szkutnik-Fiedler, Danuta
openaire +1 more source